English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Automated app-based augmented reality cognitive behavioral therapy for spider phobia: Study protocol for a randomized controlled trial

Toffolo, M. B. J., Fehribach, J. R., Van Klaveren, C. P. B. J., Cornelisz, I., Van Straten, A., Van Gelder, J.-L., et al. (2022). Automated app-based augmented reality cognitive behavioral therapy for spider phobia: Study protocol for a randomized controlled trial. PLOS ONE, 17(7): e0271175. doi:10.1371/journal.pone.0271175.

Item is

Files

show Files
hide Files
:
journal.pone.0271175.pdf (Any fulltext), 2MB
Name:
journal.pone.0271175.pdf
Description:
-
OA-Status:
Not specified
Visibility:
Public
MIME-Type / Checksum:
application/pdf / [MD5]
Technical Metadata:
Copyright Date:
-
Copyright Info:
© 2022 Toffolo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
License:
-

Locators

show

Creators

show
hide
 Creators:
Toffolo, Marieke B. J., Author
Fehribach, Jamie R., Author
Van Klaveren, Chris P. B. J., Author
Cornelisz, Ilja, Author
Van Straten, Annemieke, Author
Van Gelder, Jean-Louis1, Author           
Donker, Tara, Author
Affiliations:
1Criminology, Max Planck Institute for the Study of Crime, Security and Law, Max Planck Society, ou_2489695              

Content

show
hide
Free keywords: -
 Abstract: Background:
Fear of spiders, or Arachnophobia, is one of the most common specific phobias. The gold standard treatment, in vivo exposure therapy, is effective, but comes with significant limitations, including restricted availability, high costs, and high refusal rates. Novel technologies, such as augmented reality, may help to overcome these limitations and make Exposure Therapy more accessible by using mobile devices.
Objective:
This study will use a Randomized Controlled Trial design to investigate whether ZeroPhobia: Arachnophobia, a 6-week Augmented Reality Exposure Therapy smartphone self-help application, can effectively reduce spider phobia symptoms. Additionally, we will examine user-friendliness of the application and the effect of usage intensity and presence on treatment outcome.
Methods:
This study is registered in the Netherlands Trial Registry under NL70238.029.19 (Trial NL9221). Ethical approval was received on October 11, 2019. One-hundred-twelve participants (age 18–64, score ≥ 59) on the Fear of Spiders Questionnaire [FSQ] will be recruited from the general Dutch population and randomly assigned to a treatment or waitlist control group. The ZeroPhobia application can be accessed on users’ smartphone. Baseline, post-test (i.e., at six weeks), 3- and 12-month follow-up assessments will be done, each including the Fear of Spiders Questionnaire as the main outcome measure as well as additional measures of anxiety, depression, user-friendliness, and presence as secondary measures and covariates.
Results:
The study was funded on September 25, 2018. Data collection started in September 2021 and the study is expected to run until September 2022.
Conclusions:
Our study will improve our understanding of the efficacy and feasibility of providing Exposure Therapy for spider phobia using an Augmented Reality self-help application, with the intention of making mental health care more accessible.

Details

show
hide
Language(s): eng - English
 Dates: 2022-07-13
 Publication Status: Published online
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Type: -
 Identifiers: DOI: 10.1371/journal.pone.0271175
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: PLOS ONE
  Abbreviation : PLOS ONE
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: San Francisco, CA : Public Library of Science
Pages: - Volume / Issue: 17 (7) Sequence Number: e0271175 Start / End Page: - Identifier: ISSN: 1932-6203
CoNE: https://pure.mpg.de/cone/journals/resource/1000000000277850